Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib and Chemotherapy in AML with FLT3 Mutations
NCT02323607Phase 1Completed
- Start
- Jan 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pacritinib in acute myeloid leukemia (AML) (2 arms). Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jan 2016; status: completed.
02
Drugs
pacritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02323607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02323607.